Increased Breast Cancer Risk with Mirena IUD
The Mirena (levonorgestrel-releasing intrauterine system) is associated with a modest increased risk of breast cancer, with the most recent and highest-quality evidence showing approximately a 38% increased risk (HR 1.38), particularly elevated during the first 3 years of use.
Current Evidence on Breast Cancer Risk
The most recent large-scale study from 2025 1 provides the strongest evidence on this question. This Korean national database study of over 61,000 women found:
- Overall increased risk: Hazard ratio of 1.38 (95% CI 1.19-1.59)
- Incidence rates: 223 cases per 100,000 person-years in LNG-IUS users vs. 154 per 100,000 in non-users
- Time-dependent pattern: Risk is highest in early years and appears to decrease over time:
- First 3 years (early): HR 5.40 (95% CI 4.04-7.22) - dramatically elevated
- First 3 years (late): HR 1.04 (95% CI 0.55-2.00) - returns to baseline
- 3-5 years: HR 3.44 early, declining to 1.75 late
- 5+ years: HR 1.77 (95% CI 1.26-2.48)
Conflicting Evidence and Context
The evidence base shows significant heterogeneity:
Studies showing increased risk:
- A 2020 meta-analysis 2 found increased risk across all age groups (OR 1.16 overall, 1.52 in women ≥50 years)
- A 2016 Finnish cohort study 3 demonstrated elevated risk for both ductal (SIR 1.20) and lobular (SIR 1.33) breast cancer, with highest risk in repeat users (SIR 1.73 for lobular cancer)
Studies showing no increased risk:
- Two meta-analyses from 2021 4 and 2023 5 found no significant association
- These analyses included different study populations and methodologies, potentially explaining the discrepancy
Clinical Guidelines Framework
The U.S. Medical Eligibility Criteria (2010) 6 classifies LNG-IUD use by breast cancer status:
- Current breast cancer: Category 4 (unacceptable health risk - do not use)
- Past breast cancer (>5 years disease-free): Category 3 (risks usually outweigh benefits)
- Undiagnosed breast mass: Category 2 (benefits generally outweigh risks)
- Family history or benign disease: Category 1 (no restrictions)
The guidelines note that "breast cancer is a hormonally sensitive tumor" and acknowledge theoretical concerns about disease progression with LNG-IUD use 6.
Clinical Implications and Risk Stratification
High-risk scenarios requiring caution:
- Women with personal history of breast cancer (contraindicated if current disease)
- Strong family history or genetic predisposition (BRCA carriers)
- Age ≥50 years (higher relative risk in this group)
- Planned long-term use (>5 years)
The early peak in risk (first 3 years) 1 suggests either:
- Detection bias (increased surveillance after device insertion)
- Promotion of existing subclinical disease
- True hormonal effect on breast tissue
Important caveats:
- The absolute risk increase remains relatively small given the low baseline breast cancer incidence in reproductive-age women (72 per 100,000 in women aged 20-49) 7
- Methodological limitations exist across studies, including confounding by indication (women using LNG-IUS for menorrhagia may have different baseline risks)
- The protective effects against endometrial cancer are well-established and substantial 8
Risk-Benefit Counseling
When prescribing Mirena, explicitly discuss:
- The approximately 38% relative increase in breast cancer risk based on the most recent evidence
- The particularly elevated risk during the first 3 years of use
- Individual baseline risk factors (age, family history, breast density)
- The proven benefits for heavy menstrual bleeding and endometrial protection
- Alternative contraceptive options (copper IUD has no hormonal effects and no breast cancer association)
Consider alternative contraception in:
- Women with current or recent (<5 years) breast cancer
- Strong family history with multiple affected first-degree relatives
- Known BRCA1/2 mutations (though evidence here is mixed 9)
- Women who express significant concern about breast cancer risk
The evidence has evolved substantially, with the 2025 Korean study 1 providing the most robust and recent data suggesting a real, though modest, increased risk that clinicians should acknowledge when counseling patients about Mirena use.